Glasgow spin-out Chemify has secured more than $50 million in series B funding.

The funding round, which was oversubscribed, was co-led by Wing Venture Capital and Insight Partners, with further participation from 8VC and existing backers Eoz, Blueyard, Triatomic Capital, and Rockspring.

The new funding will enable Chemify to expand globally, as well as build a network of digital chemistry hubs to deliver on-demand molecule design and manufacturing. Its designs can be used in pharmaceutical, biotech, and material-science applications.

“Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery,” Lee Cronin, founder and chief executive said. “Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials.

“The next step in our evolution is nothing short of a revolution in the digitisation and automation of chemical discovery and manufacturing.”

This year, Chemify launched Chemifarm, a digital and automated chemistry hub designed as an advanced laboratory for the design and synthesis of molecules. The facility uses the Chemputation platform, advanced robotics, a programming language, and a curated library of validated chemical reactions.

Now, with the new funding, Chemify is looking to open a facility in Silicon Vallye, which will be led by Mike Bell, the firm’s chief technical officer. The new US hub will enhance the firm’s ability to deliver on-demand molecule design, optimising the journey from concept to compound.

Recommended reading

• 18 Glasgow Tech Startups You Need To Know About
• Glasgow’s Chemify Launches Fully Automated ‘Chemputation’ Facility
• Scottish Businesses Secure Nearly One-fifth of UK Spinout Deals

“Chemify’s technology uses automation and physical AI to enable the digitisation of chemistry, transforming chemical synthesis from an art to a programmable science,” Ansuman Satpathy, a partner at Wing Venture Capital, said.

“We are excited to support the team’s progress as they empower scientists to create novel molecules with unmatched efficiency and precision.”

Aiden Aceves, vice president at Insight Partners, remarked: “Lee is an iconoclast with the wind at his back.

“Chemify’s use of AI to ensure the make-ability of complex molecules is a paradigm shift for how medicinal chemistry is done today, and the company’s vision is matched by the strong results seen across their early pharma collaborations.”